Neuraptive Therapeutics, Inc. — Form D

Neuraptive Therapeutics, Inc. of Louisville, CO, a company, filed a Form D exempt-offering notice with the SEC on 2022-10-14. The offering totals $38.1M, of which $19.5M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (21)

NameRoleLocation
Ivan S GergelDirectorPhiladelphia, PA
Randy S HubbellDirectorPhiladelphia, PA
David S JacksonDirectorPhiladelphia, PA
Greg S ParekhDirectorPhiladelphia, PA
David S PierceDirectorPhiladelphia, PA
Robert S RadieDirectorPhiladelphia, PA
Robert S RadieExecutive OfficerPhiladelphia, PA
Evan S TzanisExecutive OfficerPhiladelphia, PA
David JacksonDirectorLouisville, CO
David JacksonExecutive OfficerLouisville, CO
David JacksonRelated PersonLouisville, CO
Gino DiSciulloDirectorLafayette, CO
Gino DiSciulloRelated PersonLafayette, CO
Greg ParekhDirectorPhiladelphia, PA
Greg ParekhRelated PersonPhiladelphia, PA
Ivan GergelDirectorPhiladelphia, PA
Ivan GergelRelated PersonPhiladelphia, PA
Randy HubbellDirectorPittsburgh, PA
Randy HubbellRelated PersonPittsburgh, PA
David M JacksonDirectorWinter Park, CO
David M JacksonExecutive OfficerWinter Park, CO

Other filings by this issuer (3)

FiledFormOfferingSold
2019-04-17D$12.5M$10.2M
2018-08-15D$100K$100K
2017-08-08D$1.0M$25K

More